New drug shows promise in early trial for rare blood disorder

NCT ID NCT05889299

Completed Disease control Sponsor: Omeros Corporation Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tested an experimental drug called OMS906 (zaltenibart) in 15 adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease where red blood cells break apart. The main goal was to check safety and how the body handles the drug. Researchers also looked for early signs that the drug might reduce red blood cell destruction and improve anemia. The study included patients not on other treatments and those already on standard therapy but with poor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OMS906 (also called zaltenibart), an experimental biologic drug
What this could lead to: If it works, this could point toward a new treatment option for PNH that helps control red blood cell breakdown and anemia.
What could go wrong: This is a very early, small study (15 people) focused on safety, not proof of effectiveness. The drug may not work in larger trials or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hemoglobinuria, Paroxysmal paroxysmal nocturnal hemoglobinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

Contacts and locations

Locations

Omeros Investigational Site

Kyiv, Ukraine

More trials for these conditions

Other studies related to the condition(s) this trial covers.